Botanix Pharmaceuticals : Change of Director's Interest Notice * 3

Appendix 3Y

Rule 3.19A.2

For personal use only

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Botanix Pharmaceuticals Limited

ABN	70 009 109 755

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Vincent Ippolito
Date of last notice	01/07/20

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest	Mr Ippolito is a trustee of the Ippolito Trust
(including registered holder)
Note: Provide details of the circumstances
giving rise to the relevant interest.
Date of change	07/07/2022
No. of securities held prior to change
Vincent Peter Ippolito	12,000,000 Unlisted Options exercisable at $0.251 expiring 18
	July 2023
Vincent Peter Ippolito	17,994,914Unlisted Options exercisable at 0.0551 each, expiring
	30 June 2022
Vincent Peter Ippolito and Karen	3,000,000 Unlisted Options exercisable at $0.115 expiring 23
Ann Ippolito	May 2023
Trust>
Class	Ordinary Shares
	Unlisted Options
Number acquired	5,286,493 Ordinary Shares
Number disposed	17,994,914 Unlisted Options

For personal use only

Value/Consideration	$0.0551 per share
Note: If consideration is non-cash, provide
details and estimated valuation
No. of securities held after the change
Vincent Peter Ippolito	5,286,493 Ordinary Shares
	12,000,000 Unlisted Options exercisable at $0.251 expiring 18
	July 2023
Vincent Peter Ippolito and Karen	3,000,000 Unlisted Options exercisable at $0.115 expiring 23
Ann Ippolito	May 2023
Trust>
Nature of change	Exercise of Unlisted Options utilising cashless exercise facility
Example: on-market trade, off-market trade,
exercise of options, issue of securities under
dividend reinvestment plan, participation in
buy-back

Part 2 - Change of director's interests in contracts - N/A

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder	N/A
(if issued securities)
Date of change	N/A
No. and class of securities to which	N/A
interest related prior to change
Note: Details are only required for a contract in
relation to which the interest has changed
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration	N/A
Note: If consideration is non-cash, provide details
and an estimated valuation
Interest after change	N/A

Part 3 - +Closed period

Were the interests in the securities or contracts detailed above	No
traded during a +closed period where prior written clearance
was required?
If so, was prior written clearance provided to allow the trade to	N/A
proceed during this period?
If prior written clearance was provided, on what date was this	N/A
provided?

Appendix 3Y

Rule 3.19A.2

For personal use only

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Botanix Pharmaceuticals Limited

ABN	70 009 109 755

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr H. William Bosch
Date of last notice	01/07/2020

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest
(including registered holder)
Note: Provide details of the circumstances
giving rise to the relevant interest.
Date of change	07/07/2022
No. of securities held prior to change	16,000,000 Ordinary Shares
	4,863,490 Unlisted Options exercisable at 0.0551 each, expiring
	30 June 2022
Class	Ordinary Shares
	Unlisted Options
Number acquired	321,551 Ordinary Shares
Number disposed	4,863,490 Unlisted Options
Value/Consideration	$0.0551 per share
Note: If consideration is non-cash, provide
details and estimated valuation
No. of securities held after change	16,321,551 Ordinary Shares

For personal use only

Nature of change

Exercise of Unlisted Options utilising cashless exercise facility

Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back

Part 2 - Change of director's interests in contracts - N/A

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder	N/A
(if issued securities)
Date of change	N/A
No. and class of securities to which	N/A
interest related prior to change
Note: Details are only required for a contract in
relation to which the interest has changed
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration	N/A
Note: If consideration is non-cash, provide details
and an estimated valuation
Interest after change	N/A

Part 3 - +Closed period

Were the interests in the securities or contracts detailed above	No
traded during a +closed period where prior written clearance
was required?
If so, was prior written clearance provided to allow the trade to	N/A
proceed during this period?
If prior written clearance was provided, on what date was this	N/A
provided?

Appendix 3Y Change of Director's Interest Notice

Appendix 3Y

Rule 3.19A.2

For personal use only

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity Botanix Pharmaceuticals Limited

ACN 009 109 755

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Stewart Washer
Date of last notice	22/02/2022

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

	Direct or indirect interest		Direct and Indirect
	Nature of indirect interest		Dr Stewart James Washer & Dr Patrizia
	(including registered holder)		Derna Washer as trustee for the Washer
	Note: Provide details of the circumstances giving rise to the
	relevant interest.		Family Trust
			(Dr Washer is a trustee and beneficiary of the
			trust)
	Date of change		21/02/2022
	No. of securities held prior to change
	Dr Stewart James Washer & Dr Patrizia Derna		4,863,490 Unlisted Options exercisable at
	Washer as trustee for the Washer Family Trust		0.0551 each, expiring 30 June 2022
	Class		Ordinary Shares
			Unlisted options
	Number acquired		321,551 Ordinary Shares
	Number disposed		4,863,490 Unlisted Options
	Value/Consideration		$0.0551 per share
	Note: If consideration is non-cash, provide details and estimated
	valuation
	+ See chapter 19 for defined terms.
			Appendix 3Y Page 1